This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Kimko, H.
Right arrow Articles by Noel, G. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimko, H.
Right arrow Articles by Noel, G. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2009, p. 3371-3374, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.01653-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections{triangledown}

Holly Kimko,1* Xu Xu,1 Partha Nandy,1 Mahesh N. Samtani,1 Richard S. Strauss,2 Partha Bagchi,1 and Gary J. Noel1

Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, New Jersey,1 Johnson & Johnson Centocor, Inc., Malvern, Pennsylvania2

Received 16 December 2008/ Returned for modification 15 March 2009/ Accepted 3 June 2009

Ceftobiprole, a broad-spectrum cephalosporin with activity against methicillin (meticillin)-resistant staphylococci, was statistically noninferior to a combination of vancomycin plus ceftazidime in patients with complicated skin and skin structure infections (cSSSI). This analysis used data from this clinical trial to determine the relationship between therapeutic outcome and the percentage of time that the unbound ceftobiprole concentration exceeds the MIC (percent T>MIC). From the trial of ceftobiprole (500 mg every 8 h, 2-h infusion) for cSSSI due to gram-positive and/or gram-negative bacteria, data from 309 patients in the microbiological intent-to-treat analysis set with measured ceftobiprole concentrations and baseline MICs were used to assess the relationship between percent T>MIC and therapeutic outcome. Individual pharmacokinetic (PK) profiles were obtained from a three-compartment population PK model. The relationship between percent T>MIC and a clinical cure was determined. For the clinical trial dosing regimen, individual percent T>MICs were used to calculate fractional target attainment rates (TARs) for ≥30 and ≥50% T>MIC targets at various MICs. There was a statistically significant relationship between achieving a ≥30 or ≥50% T>MIC and a clinical cure (P = 0.003 and P = 0.007, respectively; Pearson's {chi}2 test). The fractional TAR was greater than 90% at a MIC of ≤4 mg/liter for patients with normal renal function. A relationship between percent T>MIC and a clinical cure with ceftobiprole was demonstrated. A ceftobiprole regimen of 500 mg every 8 h as a 2-h infusion has a high probability of achieving a target of ≥30 or ≥50% T>MIC for patients with cSSSI due to gram-positive and gram-negative pathogens.

* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research & Development, LLC, 920 Route 202 South, Raritan, NJ 08869. Phone: (908) 704-5577. Fax: (908) 203-1527. E-mail: HKimko{at}its.jnj.com

{triangledown} Published ahead of print on 15 June 2009.

Antimicrobial Agents and Chemotherapy, August 2009, p. 3371-3374, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.01653-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»